Literature DB >> 12912709

Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients.

Michelle E Roland1, Bernard Lo, Jeffrey Braff, Peter G Stock.   

Abstract

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Substances:

Year:  2003        PMID: 12912709     DOI: 10.1001/archinte.163.15.1773

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


× No keyword cloud information.
  6 in total

Review 1.  Solid organ transplantation is a reality for patients with HIV infection.

Authors:  Michelle E Roland; Peter G Stock
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

2.  Solid organ transplantation and HIV: A changing paradigm.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

3.  Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience.

Authors:  Henkie P Tan; David J Kaczorowski; Amit Basu; Akhtar Khan; Jerry McCauley; Amadeo Marcos; John J Fung; Thomas E Starzl; Ron Shapiro
Journal:  Transplantation       Date:  2004-12-15       Impact factor: 4.939

4.  Liver transplantation in HCV/HIV positive patients.

Authors:  Yasuhiko Sugawara; Sumihito Tamura; Norihiro Kokudo
Journal:  World J Gastrointest Surg       Date:  2011-02-27

Review 5.  HIV-Positive Kidney Donor Selection for HIV-Positive Transplant Recipients.

Authors:  Elmi Muller; Zunaid Barday
Journal:  J Am Soc Nephrol       Date:  2018-01-12       Impact factor: 10.121

6.  Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls.

Authors:  Michelle E Roland; Burc Barin; Shirish Huprikar; Barbara Murphy; Douglas W Hanto; Emily Blumberg; Kim Olthoff; David Simon; William D Hardy; George Beatty; Peter G Stock
Journal:  AIDS       Date:  2016-01-28       Impact factor: 4.177

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.